FDA Approves Engineered B Cell Therapy ISP-001 Clinical
ADC评论
September 6, 2022
On September 1, Immusoft announced that the FDA has approved the clinical trial application of ISP-001 for mucopolysaccharidosis type I, which is the world’s first
